Immatics Reports 32% cORR in Phase 1 PRAME Melanoma Data
Immatics reported 32% cORR in PRAME-high melanoma from Phase 1b IMA402 data and 41% cORR across tumors in Phase 1 IMA203CD8 data. The company described safety as manageable and said next steps include combinations and targeted cohorts.
Immatics reported Phase 1b IMA402 results showing a 32% cORR in PRAME-high melanoma. Phase 1 IMA203CD8 data showed a 41% cORR across tumors. The safety profile was described as manageable. Planned next steps include combination studies and targeted cohorts.